Objectives: The safety and efficacy of the RevoLix 2-μ continuous wave laser for hysteroscopic myomectomy (HM) was evaluated. Materials and methods: A retrospective study was undertaken to evaluate 13 patients with symptomatic submucous myomas, who were treated with HM using a RevoLix laser application. The evaluation items included blood loss from surgery (estimated by the change between preoperative and postoperative hemoglobin levels), surgical time, amount of distension media, specimen volume retrieved, complications, and success rate. Results: The mean age of the patients was 38 years old; 10 patients were in the premenopausal status and nine patients were nullipara. The surgical time was 91 minutes, and the distension media requirement was 4500mL. The postoperative hemoglobin level decreased to 1.2g/dL compared with the preoperative status. Mean specimen volume retrieved was 13.7mm. No complications occurred. All patients reported significant improvement after HM during the 1-year follow-up. Conclusion: The use of the Revolix laser for HM seemed to be safe and effective in the management of symptomatic submucous myomas in this small population study.
- Electrosurgical operative hysteroscopy
- Hysteroscopic myomectomy
ASJC Scopus subject areas
- Obstetrics and Gynaecology